UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
14A
Proxy
Statement Pursuant to Section 14(a) of the
Securities
Exchange Act of 1934
(Amendment No. )
Filed
by the Registrant ☒
Filed
by a party other than the Registrant ☐
Check
the appropriate box:
☐ |
Preliminary
Proxy Statement |
|
|
☐ |
Confidential,
for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) |
|
|
☐ |
Definitive
Proxy Statement |
|
|
☒ |
Definitive
Additional Materials |
|
|
☐ |
Soliciting
Material under § 240.14a-12 |
AIM
ImmunoTech Inc.
(Name
of Registrant as Specified in its Charter)
(Name
of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment
of Filing Fee (Check all boxes that apply):
☒ |
No
fee required |
|
|
☐ |
Fee
paid previously with preliminary materials |
|
|
☐ |
Fee
computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
On
November 20, 2023, AIM ImmunoTech Inc. (the “Company”) began mailing the attached letter to stockholders of the Company in
connection with the Company’s 2023 annual meeting of stockholders.
November
20, 2023
Dear
Fellow Shareholders,
Thank
you for your investment in AIM ImmunoTech (“AIM” or the “Company”). We are making strong progress in the clinical
development of our pipeline to provide life-saving therapies to patients – which will allow us to deliver value for you, our shareholders.
Our
lead drug candidate, Ampligen, has excellent potential across a variety of unmet medical needs.
Ampligen’s
potential applications include treating:
| ● | Highly
lethal cancers – such as localized pancreatic cancer, metastatic triple-negative
breast cancer, and recurrent ovarian cancer; |
| ● | Debilitating
immune disorders – such as long COVID / post-COVID conditions and myalgic encephalomyelitis
/ chronic fatigue syndrome (ME/CFS); and |
| ● | A
broad spectrum of viral conditions. |
We
are well positioned to achieve multiple value-driving milestones throughout the remainder of 2023 and 2024 and have attracted world-class
collaborators.
Unfortunately,
a group of activist investors (the “Activist Group”) is attempting to take control of the AIM Board of Directors (the “Board”)
for the second year in a row.
| ● | The
Activist Group is not acting in the best interests of AIM shareholders, and we believe they
would put your investment at serious risk if they were able to take control of the Board. |
| | |
| ● | The
Board unanimously determined that the Activist Group’s nomination notice – submitted
by Ted D. Kellner – seeking to put forth three individuals for election as directors
to our four-person Board, is invalid because it omits key information – and includes
misleading information – ignoring what our Bylaws require to be disclosed. |
| ● | The
Activist Group includes many of the same individuals from last year’s effort, which
was planned and funded by convicted criminals Franz N. Tudor and Michael J. Xirinachs. |
| ● | The
Activist Group is acting selfishly by seeking reimbursement from the Company for over $5.5
million in expenses from their 2023 campaign and litigation as well as all expenses incurred
in connection with last year’s failed campaign. They intend to force you –
the AIM shareholders – to foot their bills. |
| ● | We
are currently involved in litigation the Activist Group brought against AIM, with a ruling
expected to be issued in advance of the 2023 Annual Meeting of Stockholders. |
| ● | Unless
the Court rules otherwise, the Company will not recognize the Activist Group’s attempted
nominations and any proxies submitted or votes cast for the election of the individuals from
the Activist Group will be disregarded. |
Our
current Board – comprised of Stewart L. Appelrouth, Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell – is best
positioned to ensure the Company and its shareholders capitalize on important upcoming clinical milestones and protect your investment.
We
remain committed to protecting the best interests of all shareholders.
Safeguard
AIM and your investment by voting today for the Board’s four current directors to be elected at the 2023 Annual Meeting of Stockholders
scheduled for December 1st.
To
learn more, visit: www.SafeguardAIM.com
Sincerely,
The
AIM ImmunoTech Board of Directors
***
WE
URGE YOU TO COMPLETE, DATE AND SIGN THE ENCLOSED WHITE PROXY CARD AND MAIL IT PROMPTLY IN THE POSTAGE-PAID ENVELOPE PROVIDED,
OR VOTE BY TELEPHONE OR THE INTERNET AS INSTRUCTED ON THE WHITE PROXY CARD, WHETHER OR NOT YOU PLAN TO ATTEND THE 2023 ANNUAL
MEETING.
THE
BOARD RECOMMENDS A VOTE “FOR ALL” OF OUR BOARD’S NOMINEES (STEWART L. APPELROUTH, NANCY K. BRYAN, THOMAS K.
EQUELS AND DR. WILLIAM M. MITCHELL) ON PROPOSAL 1 USING THE ENCLOSED WHITE PROXY CARD.
If
you have any questions or require any assistance in voting your shares, please contact our proxy solicitor:
Morrow
Sodali LLC
430
Park Avenue, 14th Floor
New
York, NY 10022
Stockholders
Call Toll Free: (800) 662-5200
Banks,
Brokers, Trustees, and Other Nominees Call Collect: (203) 658-9400
Email:
AIM@investor.MorrowSodali.com
About
AIM ImmunoTech Inc.
AIM
ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers,
immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called
Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials
for globally important cancers, viral diseases and disorders of the immune system.
For
more information, please visit aimimmuno.com and connect with the Company on Twitter, LinkedIn, and Facebook.
Forward-Looking
Statements
This
press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”).
Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,”
“believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well
as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of
these forward-looking statements involve a number of risks and uncertainties. The Company urges investors to consider specifically the
various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent
Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission (the “SEC”). You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those
statements, the Company claims the protection of safe harbor for forward-looking statements contained in the PSLRA. The Company does
not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
Investor
Contact:
JTC
Team, LLC
Jenene
Thomas
833-475-8247
AIM@jtcir.com
Media
Contact:
Longacre
Square Partners
Joe
Germani / Miller Winston
AIM@longacresquare.com
On
November 20, 2023, the Company posted the below message on Stocktwits and Yahoo! Finance.
We
encourage shareholders to read our latest letter which can be found at http://bit.ly/3MTtuOt. We urge you to vote on the WHITE proxy
card today FOR ALL of the Board’s director nominees.
AIM ImmunoTech (AMEX:AIM)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
AIM ImmunoTech (AMEX:AIM)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024